Header Logo

Connection

L JEFFREY MEDEIROS to Proto-Oncogene Proteins c-bcl-2

Back to Details
This is a "connection" page, showing publications L JEFFREY MEDEIROS has written about Proto-Oncogene Proteins c-bcl-2.
L JEFFREY MEDEIROS
Connection Strength
4.235
Proto-Oncogene Proteins c-bcl-2
  1. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget. 2016 Jun 21; 7(25):38122-38132.
    View in: PubMed
    Score: 0.357
  2. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015 Sep; 39(9):1250-8.
    View in: PubMed
    Score: 0.338
  3. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol. 2015 Aug; 39(8):1132-9.
    View in: PubMed
    Score: 0.336
  4. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013 Sep; 20(5):315-26.
    View in: PubMed
    Score: 0.294
  5. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012 Jan; 25(1):145-56.
    View in: PubMed
    Score: 0.258
  6. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011 May; 25(5):856-67.
    View in: PubMed
    Score: 0.248
  7. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol. 2004 Sep; 35(9):1095-100.
    View in: PubMed
    Score: 0.158
  8. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol. 2003 Jun; 200(2):240-8.
    View in: PubMed
    Score: 0.144
  9. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. Leukemia. 2023 02; 37(2):422-432.
    View in: PubMed
    Score: 0.140
  10. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol. 2002 Jun; 160(6):2309-10.
    View in: PubMed
    Score: 0.135
  11. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol. 2001 Aug; 159(2):527-35.
    View in: PubMed
    Score: 0.127
  12. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018 09; 31(9):1470-1478.
    View in: PubMed
    Score: 0.102
  13. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018 01; 32(1):8-28.
    View in: PubMed
    Score: 0.097
  14. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. Hum Pathol. 2016 12; 58:72-77.
    View in: PubMed
    Score: 0.090
  15. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Am J Surg Pathol. 2016 Feb; 40(2):253-61.
    View in: PubMed
    Score: 0.087
  16. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16.
    View in: PubMed
    Score: 0.087
  17. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol. 2015; 32(8):535-47.
    View in: PubMed
    Score: 0.086
  18. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC. J Hematol Oncol. 2015 Oct 29; 8:121.
    View in: PubMed
    Score: 0.085
  19. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
    View in: PubMed
    Score: 0.083
  20. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250.
    View in: PubMed
    Score: 0.071
  21. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63.
    View in: PubMed
    Score: 0.069
  22. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer. 2006 Apr 01; 106(7):1617-23.
    View in: PubMed
    Score: 0.044
  23. Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples. J Mol Diagn. 2004 Nov; 6(4):396-400.
    View in: PubMed
    Score: 0.040
  24. Caspase-3 activation in systemic anaplastic large-cell lymphoma. Mod Pathol. 2004 Jan; 17(1):109-16.
    View in: PubMed
    Score: 0.038
  25. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified. Mod Pathol. 2023 Dec; 36(12):100349.
    View in: PubMed
    Score: 0.037
  26. BCL-2 is consistently expressed in hyperplastic marginal zones of the spleen, abdominal lymph nodes, and ileal lymphoid tissue. Am J Surg Pathol. 2003 Jul; 27(7):888-94.
    View in: PubMed
    Score: 0.036
  27. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.035
  28. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002 Dec 01; 100(12):3935-41.
    View in: PubMed
    Score: 0.035
  29. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol. 2002 Nov; 15(11):1221-6.
    View in: PubMed
    Score: 0.035
  30. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol. 2002 Sep; 118(3):328-34.
    View in: PubMed
    Score: 0.034
  31. Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes. J Mol Diagn. 2002 Aug; 4(3):144-9.
    View in: PubMed
    Score: 0.034
  32. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res. 2002 Feb; 8(2):488-93.
    View in: PubMed
    Score: 0.033
  33. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. Hum Pathol. 2022 03; 121:36-45.
    View in: PubMed
    Score: 0.033
  34. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
    View in: PubMed
    Score: 0.033
  35. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. Mod Pathol. 2022 03; 35(3):419-426.
    View in: PubMed
    Score: 0.032
  36. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. 2021 05 01; 106(5):1381-1389.
    View in: PubMed
    Score: 0.031
  37. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
    View in: PubMed
    Score: 0.031
  38. Follicle center lymphoma and Warthin tumor involving the same anatomic site. Report of two cases and review of the literature. Am J Clin Pathol. 2000 Jan; 113(1):113-9.
    View in: PubMed
    Score: 0.029
  39. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
    View in: PubMed
    Score: 0.025
  40. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35(20):2260-2267.
    View in: PubMed
    Score: 0.024
  41. Characteristics and clinical implications of reactive germinal centers in the bone marrow. Hum Pathol. 2017 10; 68:7-21.
    View in: PubMed
    Score: 0.024
  42. Splenic marginal zone cell lymphoma. An immunophenotypic and molecular study of five cases. Am J Clin Pathol. 1996 Mar; 105(3):277-85.
    View in: PubMed
    Score: 0.022
  43. Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis. Cell Death Differ. 2013 Aug; 20(8):1080-8.
    View in: PubMed
    Score: 0.018
  44. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500.
    View in: PubMed
    Score: 0.017
  45. Genotypic analysis of diffuse, mixed cell lymphomas. Comparison with morphologic and immunophenotypic findings. Am J Clin Pathol. 1991 Apr; 95(4):547-55.
    View in: PubMed
    Score: 0.016
  46. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood. 1990 Nov 15; 76(10):2086-90.
    View in: PubMed
    Score: 0.015
  47. Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med. 2010 Jun; 14(6B):1532-45.
    View in: PubMed
    Score: 0.014
  48. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006 Jan; 19(1):25-33.
    View in: PubMed
    Score: 0.011
  49. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005 Jun; 18(6):806-15.
    View in: PubMed
    Score: 0.010
  50. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53.
    View in: PubMed
    Score: 0.009
  51. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003 Apr; 127(4):424-31.
    View in: PubMed
    Score: 0.009
  52. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2003 Jan; 199(1):90-7.
    View in: PubMed
    Score: 0.009
  53. Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol. 2002 Apr; 117(4):574-80.
    View in: PubMed
    Score: 0.008
  54. Real-Time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences. Mod Pathol. 2002 Apr; 15(4):448-53.
    View in: PubMed
    Score: 0.008
  55. Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases. Mod Pathol. 2001 Nov; 14(11):1093-9.
    View in: PubMed
    Score: 0.008
  56. Follicular center cell lymphoma with the t(14;18) translocation in which the rearranged BCL-2 gene is silent. Leukemia. 1993 Nov; 7(11):1834-9.
    View in: PubMed
    Score: 0.005
  57. bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. Am J Clin Pathol. 1993 May; 99(5):604-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.